Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 2
2004 1
2005 5
2006 3
2008 1
2009 7
2010 4
2011 10
2012 12
2013 27
2014 19
2015 17
2016 9
2017 16
2018 17
2019 12
2020 10
2021 22
2022 31
2023 38
2024 25
2025 29

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

294 results

Results by year

Filters applied: . Clear all
Page 1
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis.
Payne AB, Watts JA, Mitchell PK, Dascomb K, Irving SA, Klein NP, Grannis SJ, Ong TC, Ball SW, DeSilva MB, Natarajan K, Sheffield T, Bride D, Arndorfer J, Naleway AL, Koppolu P, Fireman B, Zerbo O, Timbol J, Goddard K, Dixon BE, Fadel WF, Rogerson C, Allen KS, Rao S, Mayer D, Barron M, Reese SE, Rowley EAK, Najdowski M, Ciesla AA, Mak J, Reeves EL, Akinsete OO, McEvoy CE, Essien IJ, Tenforde MW, Fleming-Dutra KE, Link-Gelles R. Payne AB, et al. Among authors: naleway al. Lancet. 2024 Oct 19;404(10462):1547-1559. doi: 10.1016/S0140-6736(24)01738-0. Lancet. 2024. PMID: 39426837
A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation.
Long-Term Oxygen Treatment Trial Research Group; Albert RK, Au DH, Blackford AL, Casaburi R, Cooper JA Jr, Criner GJ, Diaz P, Fuhlbrigge AL, Gay SE, Kanner RE, MacIntyre N, Martinez FJ, Panos RJ, Piantadosi S, Sciurba F, Shade D, Stibolt T, Stoller JK, Wise R, Yusen RD, Tonascia J, Sternberg AL, Bailey W. Long-Term Oxygen Treatment Trial Research Group, et al. N Engl J Med. 2016 Oct 27;375(17):1617-1627. doi: 10.1056/NEJMoa1604344. N Engl J Med. 2016. PMID: 27783918 Free PMC article. Clinical Trial.
Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, Donahue JG, Kharbanda EO, Naleway A, Nelson JC, Xu S, Yih WK, Glanz JM, Williams JTB, Hambidge SJ, Lewin BJ, Shimabukuro TT, DeStefano F, Weintraub ES. Klein NP, et al. Among authors: naleway a. JAMA. 2021 Oct 12;326(14):1390-1399. doi: 10.1001/jama.2021.15072. JAMA. 2021. PMID: 34477808 Free PMC article.
Intrinsic immunogenicity is a major determinant of type-specific responses in SARS-CoV-2 infections.
Quirk GE, Schoenle MV, Peyton KL, Uhrlaub JL, Lau B, Liang CY, Burgess JL, Ellingson K, Beitel S, Romine J, Lutrick K, Fowlkes A, Britton A, Tyner HL, Caban-Martinez AJ, Naleway A, Gaglani M, Yoon S, Edwards LJ, Olsho L, Dake M, Valdez R, Gordon A, Diamond MS, LaFleur BJ, Nikolich JŽ, Sprissler R, Worobey M, Bhattacharya D. Quirk GE, et al. Among authors: naleway a. Nat Immunol. 2025 Jun;26(6):829-836. doi: 10.1038/s41590-025-02162-2. Epub 2025 May 27. Nat Immunol. 2025. PMID: 40425779 Free PMC article.
Polymorphous light eruption.
Naleway AL. Naleway AL. Int J Dermatol. 2002 Jul;41(7):377-83. doi: 10.1046/j.1365-4362.2002.01467.x. Int J Dermatol. 2002. PMID: 12121545 Review. No abstract available.
Influenza Vaccine Effectiveness Against Illness and Asymptomatic Infection in 2022-2023: A Prospective Cohort Study.
White EB, Grant L, Mak J, Olsho L, Edwards LJ, Naleway A, Burgess JL, Ellingson KD, Tyner H, Gaglani M, Lutrick K, Caban-Martinez A, Newes-Adeyi G, Duque J, Yoon SK, Phillips AL, Thompson M, Britton A, Flannery B, Fowlkes A. White EB, et al. Among authors: naleway a. Clin Infect Dis. 2025 Apr 30;80(4):893-900. doi: 10.1093/cid/ciae491. Clin Infect Dis. 2025. PMID: 39446477
Infant Respiratory Syncytial Virus Immunization Coverage in the Vaccine Safety Datalink: 2023-2024.
Irving SA, Crane B, Weintraub ES, Patel SA, Razzaghi H, Daley MF, Dixon B, Donahue JG, Fuller CC, Fuller S, Getahun D, Glenn SC, Hambidge SJ, Jackson LA, Jacobson KB, Kharbanda EO, Maro JC, O'Leary ST, Schmidt T, Sznajder K, Weinfield NS, Williams JTB, Zerbo O, Naleway AL. Irving SA, et al. Among authors: naleway al. Pediatrics. 2025 Jun 1;155(6):e2024070240. doi: 10.1542/peds.2024-070240. Pediatrics. 2025. PMID: 40324788
Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years - VISION and IVY Networks, September 2024-January 2025.
Link-Gelles R, Chickery S, Webber A, Ong TC, Rowley EAK, DeSilva MB, Dascomb K, Irving SA, Klein NP, Grannis SJ, Barron MA, Reese SE, McEvoy C, Sheffield T, Naleway AL, Zerbo O, Rogerson C, Self WH, Zhu Y, Lauring AS, Martin ET, Peltan ID, Ginde AA, Mohr NM, Gibbs KW, Hager DN, Prekker ME, Mohamed A, Johnson N, Steingrub JS, Khan A, Felzer JR, Duggal A, Wilson JG, Qadir N, Mallow C, Kwon JH, Columbus C, Vaughn IA, Safdar B, Mosier JM, Harris ES, Chappell JD, Halasa N, Johnson C, Natarajan K, Lewis NM, Ellington S, Reeves EL, DeCuir J, McMorrow M, Paden CR, Payne AB, Dawood FS, Surie D; CDC COVID-19 Vaccine Effectiveness Collaborators. Link-Gelles R, et al. Among authors: naleway al. MMWR Morb Mortal Wkly Rep. 2025 Feb 27;74(6):73-82. doi: 10.15585/mmwr.mm7406a1. MMWR Morb Mortal Wkly Rep. 2025. PMID: 40014628 Free PMC article.
294 results